Business
Nov 23, 2025 · tact.cgkik.top

Bayer reports positive results for blood thinner after 2023 setback

BERLIN (Reuters) -German pharma company Bayer reported positive study ​results for its anticoagulant asundexian on Sunday,‌ two years after a research setback for the ‌promising blood thinner candidate.

In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared ⁠with a placebo,‌ Bayer said.

Detailed results from the OCEANIC-STROKE study will be presented ‍at an upcoming scientific congress, said Bayer.

Bayer added that it plans to speak with health ​authorities worldwide in preparation for the submission ‌of marketing authorisation applications.

Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any ⁠of its other drugs.

At ​the end of 2023,​ the company had a major setback with the drug after it failed ‍in a ⁠pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.

($1 ⁠= 0.8687 euros)

(Reporting by Joern Poltz.‌ Writing by Miranda Murray. ‌Editing by Jane Merriman)

You Might Also Like

News

Russian drone slams into block of flats in deadly wave of strikes across Kyiv

News

Ancient meditation practices find new life in modern religious communities across America

News

A red meat allergy from tick bites is spreading – and the lone star tick isn’t the only alpha-gal carrier to worry about

News

Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up